Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | rhEndostatin + Rivoceranib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rivoceranib | YN968D1|Apatinib | KIT Inhibitor 57 RET Inhibitor 53 SRC Inhibitor 31 VEGFR2 Inhibitor 37 | Rivoceranib (apatinib) is an inhibitor of receptor tyrosine kinases, including KDR (VEGFR2), RET, c-KIT, Src, and PDGFRa, which may result in reduced cell proliferation and inhibition of tumor growth (PMID: 21443688, PMID: 32669874). | |
rhEndostatin | Recombinant Human Endostatin|Recombinant Endostatin|Endostar|Endostatin | rhEndostatin is recombinant human endostatin, which may lead to suppression of Vegfr signaling and inhibition of tumor angiogenesis and growth (PMID: 17644065). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|